UroGen Pharma Ltd. (URGN)

UroGen Pharma Ratios and Metrics

Market cap in millions USD. Fiscal year is January - December.

Fiscal Year	Current	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jan 16, 2026	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Market Capitalization	880	449	463	205	213	398
Market Cap Growth	95.82%	-2.93%	126.06%	-3.94%	-46.44%	-43.13%
Enterprise Value	883	318	409	184	105	276
Last Close Price	18.80	10.65	15.00	8.87	9.51	18.02
PS Ratio	9.27	4.97	5.60	3.18	4.44	33.74
PB Ratio	-	-51.05	-7.10	-2.29	25.34	4.13
P/TBV Ratio	-	-	-	-	25.34	4.13
EV/Sales Ratio	9.14	3.52	4.95	2.85	2.18	23.36
Debt / Equity Ratio	-1.13	-14.19	-1.54	-1.12	0.18	0.03
Asset Turnover	0.40	0.39	0.53	0.50	0.40	0.07
Inventory Turnover	1.46	1.19	1.87	1.67	1.52	-
Quick Ratio	3.47	5.59	4.88	4.71	4.51	5.09
Current Ratio	3.99	6.01	5.42	5.39	5.11	5.39
Return on Equity (ROE)	-	-	-	-	-211.55%	-92.88%
Return on Assets (ROA)	-33.96%	-25.77%	-26.10%	-38.69%	-47.72%	-46.29%
Return on Capital (ROIC)	-101.59%	-79.15%	-179.24%	-479.55%	-105.88%	-52.96%
Return on Capital Employed (ROCE)	-92.60%	-39.90%	-44.60%	-70.80%	-94.80%	-119.50%
Earnings Yield	-18.71%	-28.23%	-22.08%	-53.60%	-51.98%	-32.27%
FCF Yield	-15.70%	-21.60%	-16.54%	-42.88%	-40.17%	-26.90%
Buyback Yield / Dilution	-18.43%	-48.70%	-26.43%	-2.05%	-2.60%	-6.10%

Updated Nov 6, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q